Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL28239246 | 0.92 | THRB (0.55) | THRBSMN1; SMN2LMNAALDH1A1HSD17B10 | |
| 1,4-Butanediol SCHEMBL7613410 | 0.92 | THRB (0.61) | THRBSMN1; SMN2LMNAALDH1A1PSMD14 | |
| SCHEMBL28179960 | 0.92 | — | — | |
| SCHEMBL4162036 | 0.92 | — | — | |
| SCHEMBL10902826 | 0.92 | THRB (0.61) | THRBSMN1; SMN2LMNAALDH1A1PSMD14 | |
| SCHEMBL35437 | 0.92 | — | — | |
| Butyl Alcohol SCHEMBL28472879 | 0.90 | ALDH1A1 (0.52) | THRBSMN1; SMN2LMNAALDH1A1HSD17B10 | |
| SCHEMBL6757071 | 0.90 | SMN1; SMN2 (0.50) | THRBSMN1; SMN2LMNAALDH1A1HSD17B10 | |
| SCHEMBL3967156 | 0.89 | THRB (0.58) | THRBSMN1; SMN2LMNAALDH1A1HSD17B10 | |
| SCHEMBL8624500 | 0.89 | THRB (0.58) | THRBSMN1; SMN2LMNAALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487513-B1 | BIODEGRADABLE HYDROPHOBIC POLYMER FOR STENTS | ABBOTT CARDIOVASCULAR SYSTEMS (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-1503763-B1 | THERAPEUTIC 1,2,3,6-TETRAHYDROPYRIMIDINE-2-ONE COMPOSITIONS AND METHODS THEREWITH | CRAGMONT PHARMACEUTICALS LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080280978-A1 | Insect Repellent Compositions | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2008-11-13 | — | — | US | disclosed |
| US-7285534-B2 | Corticotropin-releasing hormone analogs and their uses | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-10-23 | — | — | US | disclosed |
| US-6919348-B2 | Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith | CRAGMONT PHARMACEUTICALS, LLC | 2005-07-19 | — | — | US | disclosed |
| US-20050096275-A1 | Novel corticotropin-releasing hormone analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-05-05 | — | — | US | disclosed |
| EP-1503763-A1 | THERAPEUTIC 1,2,3,6-TETRAHYDROPYRIMIDINE-2-ONE COMPOSITIONS AND METHODS THEREWITH | Cragmont Pharmaceuticals, LLC (US) | 2005-02-09 | — | — | EP | disclosed |
| US-6849600-B2 | Corticotropin-releasing hormone analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, BERKELEY (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1487513-A1 | BIODEGRADABLE HYDROPHOBIC POLYMER FOR STENTS | Advanced Cardiovascular Systems, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-6803359-B2 | ADMINISTERING A MEMBER OF THE CORTICOTROPIN- RELEASING HORMONE (CRH) SUPERFAMILY OR ANALOG FOR INHIBITING CANCEROUS TUMOR GROWTH IN MAMMALS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-10-12 | — | — | US | disclosed |
| US-20030207851-A1 | Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith | CRAGMONT PHARMACEUTICALS, LLC | 2003-11-06 | — | — | US | disclosed |
| US-20030186853-A1 | Novel corticotropin-releasing hormone analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, OFFICE OF TECHNOLOGY TRANSFER (US) | 2003-10-02 | — | — | US | disclosed |
| WO-2003080147-A1 | BIODEGRADABLE HYDROPHOBIC POLYMER FOR STENTS | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2003-10-02 | — | — | WO | disclosed |
| EP-1214347-B1 | INHIBITION OF ABNORMAL CELL GROWTH WITH CORTICOTROPIN-RELEASING HORMONE ANALOGS | UNIV CALIFORNIA (US) | 2003-06-04 | — | — | EP | disclosed |
| US-20020142962-A1 | Administering a member of the corticotropin- releasing hormone (CRH) superfamily or analog for inhibiting cancerous tumor growth in mammals | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-10-03 | — | — | US | disclosed |
| EP-1214347-A2 | INHIBITION OF ABNORMAL CELL GROWTH WITH CORTICOTROPIN-RELEASING HORMONE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-06-19 | — | — | EP | disclosed |
| US-6319900-B1 | ADMINISTERING PEPTIDE ANALOG OF A CORTICOTROPIN-RELEASING HORMONE (CRH) HAVING THE AMINO ACID SEQUENCE OF HUMAN CRH WHEREIN THE 2OTH AMINO ACID FROM N-TERMINUS IS D-AMINO ACID FOR THERAPY OF INFLAMMATORY DEMATOSES PSORIATIC CONDITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-11-20 | — | — | US | disclosed |
| WO-2001021191-A2 | INHIBITION OF ABNORMAL CELL GROWTH WITH CORTICOTROPIN-RELEASING HORMONE ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-03-29 | — | — | WO | disclosed |
| US-5897857-A | SULFHYDRYL COMPOUND SELECTED FROM CYSTEINE, HOMOCYCTEINE, GLUTATHIONE, THIOGLYCEROL, THIOMALIC ACID, 2-MERCAPTOETHANOL, MERCAPTOPROPIONIC ACIDS, DITHIOTHREITOL, THIOSALICYLIC ACID, N-ACETYL-L-CYSTEIN AND SALTS; FACIAL HAIR REMOVER | THE PROCTER & GAMBLE COMPANY (US) | 1999-04-27 | — | — | US | disclosed |
| US-5869521-A | Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith | ADOLOR CORPORATION (US) | 1999-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207851-A1 | Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith | HRH2, HRH4, HRH1 | THRB 876/4885SMN1; SMN2 1546/4885LMNA 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.